Alkion BioInnovations

Alkion BioInnovations is pioneering the bioproduction of QS-21, a powerful vaccine adjuvant, using advanced plant tissue culture in automated bioreactors.
Our process starts with elicited Quillaja saponaria cell cultures, grown in temporary immersion bioreactors, ensuring sustainable, non-destructive sourcing.
We’ve integrated robotics and AI-driven controls to optimize growth, yield, and consistency at scale.
Our upstream process leverages elicitation and metabolic engineering to boost saponin production.
The downstream process involves tailored extraction and purification protocols for high-purity QS-21, compliant with pharmaceutical standards.
Our platform reduces variability, enhances traceability, and eliminates reliance on endangered wild trees.
We can deliver ultrapure QS-21 for human vaccines, and co-products for veterinary adjuvants.
Alkion’s proprietary process supports GMP scale-up, ensuring supply chain resilience.
We are actively collaborating with vaccine developers to validate AS01-like systems using our QS-21.
Alkion offers a unique, scalable, and sustainable solution for next-generation vaccine adjuvants.